The direct answer
Iron tablets cause stomach pain because iron salts are directly toxic to the gastric epithelium — the cellular layer lining your stomach wall. This is not an unusual reaction, and it is not a sign of a weak stomach. It is a predictable chemical consequence of how ferrous sulphate behaves when it dissolves in gastric fluid.
When a ferrous sulphate tablet dissolves in the stomach, it releases free iron ions directly into contact with the gastric mucosa. Iron ions are chemically reactive. They undergo the Fenton reaction: iron reacts with hydrogen peroxide naturally present in gastric tissue to generate hydroxyl radicals — one of the most damaging classes of reactive oxygen species (ROS).
Hydroxyl radicals attack the lipid membranes of gastric epithelial cells, causing oxidative damage to the mucosal surface. The body responds with localised inflammation. Mucus secretion is disrupted. Nerve endings in the epithelium are activated. That activation is the pain.
Iron's stomach pain is driven by reactive oxygen species from the Fenton reaction, not excess acid production. This distinction matters: antacids reduce acid but do not inhibit the Fenton reaction, block ROS generation, or repair the mucosal damage. The burning sensation is similar to acid-related pain — which is why antacids are the instinctive response — but the mechanism is completely different.
What iron does to the stomach lining
Ferrous sulphate dissolves rapidly in gastric acid, releasing free Fe²⁺ ions. The faster the dissolution, the more free ions are available in the gastric environment at once — which is why slow-release or chelated forms cause less irritation.
Step 1Free iron reacts with hydrogen peroxide naturally present in gastric tissue. The reaction generates hydroxyl radicals (OH•) — among the most reactive and destructive compounds in biological chemistry. The reaction is catalytic, meaning a small amount of iron generates a large quantity of radicals.
Step 2 — Key reactionHydroxyl radicals initiate lipid peroxidation in gastric epithelial cell membranes. At low concentrations this causes reversible irritation. At higher concentrations or with a compromised mucosa, it causes cell death and surface erosion.
Step 3Oxidative stress from hydroxyl radicals activates NF-kB — the master inflammatory transcription factor. NF-kB drives production of IL-8, TNF-α, and pro-inflammatory cytokines that recruit immune cells to the gastric mucosa, amplifying the initial chemical damage into a sustained inflammatory state.
Step 4Active NF-kB signalling inhibits the EGFR/ERK pathway — the stomach's primary mucosal repair mechanism. The stomach is being damaged and simultaneously prevented from fully repairing itself between doses.
Step 5Ferrous sulphate supplementation causes significantly more gastrointestinal side effects than other iron preparations across all major symptom categories — a consequence of direct oxidative damage to the gastric mucosal surface, not acid-related irritation.
Why the pain is worse for some people than others
The stomach's resistance to iron's oxidative effects depends on the integrity of its mucosal layer — a gel-like coating secreted by goblet cells that sits between the gastric lining and its contents. When that layer is healthy, it buffers iron's direct contact with the epithelium. When it is thinned or compromised, iron has direct access.
Two conditions create this vulnerability in large numbers of Indian patients:
H. pylori actively degrades the gastric mucus layer through its virulence factors, reducing the protective buffer exactly where iron will make contact. The TumGard India Gut Health Report 2026 found that 62% of Indians with gut symptoms who underwent endoscopy tested positive for H. pylori. Many of these same patients are also iron-deficient, since H. pylori impairs iron absorption — meaning they are prescribed iron precisely when their mucosal defences are at their weakest.
Existing gastritis progressively erodes the gastric epithelium. In these patients, the same iron dose that causes mild discomfort in a healthy stomach can cause significant, lasting pain — because the surface iron contacts is already damaged and the EGFR/ERK repair cycle is already suppressed.
Why ferrous sulphate causes more pain than other forms
Ferrous sulphate is a simple inorganic salt. It dissolves quickly in gastric fluid and releases free iron ions rapidly — maximising the duration and surface area of direct mucosal contact. Chelated forms like ferrous bisglycinate bind iron to amino acids, slowing the release of free ions and reducing direct mucosal exposure. Clinical reviews consistently report lower rates of gastric pain with chelated preparations at equivalent elemental iron doses.
Ferrous sulphate is the default prescription in India because it is inexpensive. The gastric side effect burden is a known trade-off. It is rarely explained to patients as a consequence of the form rather than the iron itself — which matters, because the form can be changed.
References
- Tolkien Z et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLOS ONE. 2015;10(2):e0117383. PMID 25700159. Meta-analysis confirming ferrous sulphate causes more GI side effects than other iron forms — including nausea, constipation, and upper abdominal pain — through oxidative rather than acid mechanisms.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Defines the EGFR/ERK mucosal repair pathway and its suppression by active inflammatory states, including NF-kB-driven inflammation.
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Establishes H. pylori's mechanism of mucosal damage through NF-kB activation and EGFR/ERK suppression — the same pathway iron's oxidative stress exacerbates.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 62% H. pylori positivity rate among endoscoped Indian adults with gut symptoms (n=1,111 endoscopy sub-cohort of 20,363 total survey).
The 62% H. pylori positivity rate cited in this article is drawn from TumGard's endoscopy sub-cohort of 1,111 buyers — not general population data. These are symptomatic individuals who sought gut health support, and as such likely represent a population with higher-than-average H. pylori prevalence. General population estimates for India range from 40–60%. The overlap with the iron-supplementing population is a clinical inference supported by the known relationship between H. pylori and iron deficiency anaemia.